n CME : Your SA Journal of CPD - Long-acting beta2-adrenergic agonists and the smart trial : medifile
|Article Title||Long-acting beta2-adrenergic agonists and the smart trial : medifile|
|© Publisher:||Health and Medical Publishing Group (HMPG)|
|Journal||CME : Your SA Journal of CPD|
|Publication Date||Jun 2006|
|Pages||333 - 335|
Extracted from text ... Medifile MEDIFILE The FDA issued an advisory late in 2005, warning that long-acting ?2-adrenergic agonists (LABAs) may increase the chance of severe asthma exacerbations, which may result in death. An increase in deaths was first ascribed to salmeterol in the Serevent Nationwide Surveillance (SNS) study, conducted by the Glaxo research group in the early 1990s. This study compared the safety of salmeterol and salbutamol in treating asthmatic patients, and the results indicated a small but non-significant excess mortality in the group taking salmeterol and a significant excess of asthma events including deaths in patients with severe asthma on entry. ..
Article metrics loading...